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Background: Apixaban is an oral direct factor Xa inhibitor under development for secondary prevention in acute coronary syndromes (ACS). 
Apixaban[[Unsupported Character - &#900;]]s effect on D-dimer, prothrombin fragment 1+2 (F1+2) (coagulant activity), C- reactive protein (hsCRP), 
fibrinogen and other inflammatory markers was assessed in a randomized, double-blinded, placebo-controlled, phase 2 study. .
Methods: Patients (n=1715) with ACS received placebo or apixaban 2.5 mg BID, 10 mg QD, 10 mg BID, 20 mg QD for 6 months. All patients 
received aspirin <165 mg; 76% also received clopidogrel 75 mg. Samples were obtained at baseline, weeks 3 and 26.
Results: Most patients had elevated D-dimer and F1+2 levels at baseline. Both biomarkers decreased by week 3 in all groups, but to a greater 
degree with apixaban than placebo (P<0.001).While the overall degree of suppression did not differ significantly among the three highest doses, 
F1.2 was suppressed more rapidly by 10 mg QD than 2.5 mg BID (P<0.05).Coagulant activity persisted at week 26 in 25% of placebo and only 6% of 
apixaban-treated patients(P<0.001). There was a direct relation between apixaban plasma concentrations and anti-Xa levels, and an inverse relation 
with coagulant activity. HsCRP and fibrinogen declined in all patients over time (table).
Conclusion: Apixaban, an oral direct factor Xa inhibitor significantly and more rapidly reduced D-dimer and F1+2 levels toward normal values 
compared with placebo. 
Median Biomarker Values
Reference 
Interval Sample 
Placebo
(n=611) 
Apixaban 2.5 mg BID
(n=317)
Apixaban 10 mg QD
(n=318)
Apixaban 10 mg BID
(n=248)
Apixaban 20 mg QD
(n=221)
N
(baseline) 582 306 305 227 203
D-dimer (ng/mL) (0-251)
Predose 317 325 325 314 321
Week 3 258 206 185 176 185
Week 26 207 172 163 * *
F1+2 (pmole/L) (87-325)
Predose 299 309 307 328 332
Week 3 267 201 161 167 157
Week 26 246 191 184 * *
hsCRP (mg/L) (0.068-8.2)
Predose 23.1 22.7 21.7 25.5 21.7
Week 3 4.45 3.81 4.21 4.34 4.41
Week 26 3.65 3.07 3.52 * *
Fibrinogen (mg/
dL) (206-382)
Predose 478 472 458 470 471
Week 3 372 367 372 359 375
Week 26 331 325 337 * *
*Patient number < 20 due to dose discontinuation
